Dr. Pian Liu 刘翩
Chief Physician, Associate Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of thoracic tumors, including lung cancer, esophageal cancer, and mediastinal tumors. Expertise in diagnosis and individualized therapy using radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy.
Dr. Liu holds an MD and studied in the United States. A Chief Physician and Associate Professor, Dr. Liu focuses on malignant tumor prevention and precise treatment. Dr. Liu has led two National Natural Science Foundation projects, participated in several others, and published over ten SCI papers.
Professional roles
- Member, Hubei Society of Medical Biology and Immunology
- Standing Committee Member, Immunotherapy Expert Committee, Hubei Clinical Oncology Society (ESCO)
- Member, Lung Tumor Professional Committee, China Medicine Education Association
Name order: in Chinese the family name comes first (Liu Pian). Papers usually list the name as Pian Liu or Liu P.
Selected publications
33 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Exp Neurol, 2026 (senior author): Molecular characteristics and modifications of glioblastoma affecting the efficacy of immunotherapy. PubMed 42341896
- Cell Oncol (Dordr), 2026 (senior author): ITGB5 promotes immune escape in hepatocellular carcinoma by regulating PD-L1 through SETDB1/Hippo signaling pathway. PubMed 42371237
- Oncogene, 2025 (senior author): C1QBP forms a positive feedback loop with the PAICS/FAK/C-MYC axis to promote cancer cell proliferation. PubMed 41028903
- Stem Cell Res Ther, 2025 (senior author): The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials. PubMed 40158191
- Discov Oncol, 2025 (senior author): The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance. PubMed 40100307
- Crit Rev Oncol Hematol, 2025 (senior author): STAT3 orchestrates immune dynamics in hepatocellular carcinoma: A pivotal nexus in tumor progression. PubMed 39818308
- J Hepatocell Carcinoma, 2024 (senior author): ZDHHC20 Activates AKT Signaling Pathway to Promote Cell Proliferation in Hepatocellular Carcinoma. PubMed 39309302
- J Hepatocell Carcinoma, 2024 (senior author): Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma. PubMed 38250308
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion